NCT02844816: A reported trial by National Cancer Institute (NCI)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02844816 |
|---|---|
| Title | Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 13, 2017 |
| Completion date | June 1, 2023 |
| Required reporting date | May 31, 2024, midnight |
| Actual reporting date | Oct. 17, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |